Cohort (n = 96) | Low-NTR (n = 44) | High-NTR (n = 52) | p-valueb | ||
---|---|---|---|---|---|
Gender | Male | 88 (92%) | 41 (93%) | 47 (90%) | 0.723 |
Female | 8 (8%) | 3 (7%) | 5 (10%) | ||
Age at diagnosisa | 53.2 [49.0–58.5] | 53.5 [48.9–59.6] | 52.7 [49.0–58.2] | 0.938 | |
Previous cancer history | No | 92 (96%) | 42 (96%) | 50 (96%) | 1.000 |
Yes | 4 (4%) | 2 (5%) | 2 (5%) | ||
Performance status | ECOG 0–1 | 93 (97%) | 41 (93%) | 52 (100%) | 0.093 |
ECOG 2–3 | 3 (3%) | 3 (7%) | 0 (0%) | ||
Differentiation | Well to Moderate | 68 (77%) | 33 (83%) | 35 (73%) | 0.318 |
Poor | 20 (23%) | 7 (18%) | 13 (27%) | ||
Missing | 8 | 4 | 4 | ||
Tumor lengtha(cm) | 7.0 [5.7–8.4] | 7.2 [5.6–9.0] | 7.0 [5.8–8.0] | 0.459 | |
Tumor location | Cervical | 22 (23%) | 11 (25%) | 11 (21%) | 0.716 |
Upper third | 31 (32%) | 12 (27%) | 19 (37%) | ||
Middle third | 40 (42%) | 19 (43%) | 21 (40%) | ||
Lower third | 3 (3%) | 2 (5%) | 1 (2%) | ||
Nodal stage (AJCC 7th edition) | N0-N1 | 14 (15%) | 9 (21%) | 5 (10%) | 0.028 |
N2 | 52 (54%) | 27 (61%) | 25 (48%) | ||
N3 | 30 (31%) | 8 (18%) | 22 (42%) | ||
First RT dosea(Gy) | < 40 Gy | 45 (47%) | 14 (32%) | 31 (60%) | 0.007 |
> = 40 Gy | 51 (53%) | 30 (68%) | 21 (40%) | ||
Chemotherapy regimen | Cisplatin + 5-FU | 68 (71%) | 28 (64%) | 40 (77%) | 0.064 |
Carboplatin + Paclitaxel | 24 (25%) | 12 (27%) | 12 (23%) | ||
Cisplatin + Paclitaxel | 4 (4%) | 4 (9%) | 0 (0%) | ||
SUVTumora | 18.3 [14.8–23.2] | 18.3 [15.6–24.4] | 17.8 [13.3–21.7] | 0.107 | |
SUVLNa | 9.2 [4.4–14.3] | 4.4 [3.1–6.8] | 13.7 [10.8–16.8] | < 0.001 | |
NTRa | 0.52 [0.24–0.80] | 0.22 [0.13–0.31] | 0.77 [0.65–0.98] | < 0.001 |